Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 Nov;165(5):1206-1218.
doi: 10.1053/j.gastro.2023.07.018. Epub 2023 Aug 3.

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Affiliations
Free article
Meta-Analysis

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Vivek C Goodoory et al. Gastroenterology. 2023 Nov.
Free article

Erratum in

  • Corrigendum.
    [No authors listed] [No authors listed] Gastroenterology. 2024 Nov;167(6):1248. doi: 10.1053/j.gastro.2024.08.017. Epub 2024 Aug 29. Gastroenterology. 2024. PMID: 39207347 No abstract available.

Abstract

Background & aims: Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.

Methods: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.

Results: We identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.

Conclusions: Some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.

Keywords: Abdominal Bloating; Abdominal Pain; Irritable Bowel Syndrome; Meta-analysis; Probiotics.

PubMed Disclaimer

Comment in

MeSH terms

LinkOut - more resources